Establishment of stable multilineage hematopoietic chimerism and donor- specific tolerance without irradiation

Transplantation

Volumn 69, Issue 7, 2000, Pages 1242-1251

  Hale, Douglas A ^a   Gottschalk, Rita ^a   Umemura, Akihisa ^a   Maki, Takashi ^a   Monaco, Anthony P ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; LYMPHOCYTE ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN; RAPAMYCIN;

ALLOIMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHIMERA; FLOW CYTOMETRY; GRAFT SURVIVAL; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE; MALE; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN ALLOGRAFT;

EID: 0034655708     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200004150-00008     Document Type: Article

References (69)

1. Billingham RE, Brent L, Medawar PG. Quantitative studies on tissue transplantation immunity. III. Actively acquired tolerance. Phil Trans Roy Soc London 1955; 239: 357.
2. Streilein JW. Neonatal tolerance of H-2 alloantigens: procuring graft acceptance the "old-fashioned" way [see comments]. Transplantation 1991; 52(1): 1.
3. Lee LA, Sergio JJ, Sachs DH, Sykes M. Mechanism of tolerance in mixed xenogeneic chimeras prepared with a nonmyeloablative conditioning regimen. Transplant Proc 1994; 26: 1197.
4. Ildstad ST, Boggs SS, Vecchini F, et al. Mixed xenogeneic chimeras (rat + mouse to mouse): evidence of rat stem cell engraftment, strain-specific transplantation tolerance, and skin-specific antigens. Transplantation 1992; 53(4): 815.
5. Ildstad ST, Wren SM, Oh E, Hronakes ML. Mixed allogeneic reconstitution (A+B - A) to induce donor-specific transplantation tolerance: permanent acceptance of a simultaneous donor skin graft. Transplantation 1991; 51: 1262.
6. Monaco AP, Wood ML. Studies on heterologous antilymphocyte serum in mice. VII. Optimal cellular antigen for induction of immunologic tolerance with antilymphocyte serum. Transplant Proc 1970; 2: 489.
7. Gozzo J, Wood ML, Monaco AP. Use of allogenic, homozygous bone marrow cells for the induction of specific immunologic tolerance in mice treated with antilymphocyte serum. Surg Forum 1970; 21: 243.
8. Monaco A, Liegeois A, Wood M, Clark A. Active enhancement of tissue allografts with antilymphocyte serum and bone marrow. In: Hamburger, Crosnier, Maxwell, eds. Advances in nephrology, vol 5. Littleton, Massachusetts: Year Book Medical Publishers, 1975: 135.
9. Wood ML, Orosz CG, Gottschalk R, Monaco AP. The effect of injection of donor bone marrow on the frequency of donor-reactive CTL in antilymphocyte serum-treated, grafted mice. Transplantation 1992; 54: 665.
10. Wood ML, Monaco AP. Suppressor cells in specific unresponsiveness to skin allografts in ALS-treated, marrow-injected mice. Transplantation 1980; 29: 196.
11. Monaco AP, Wood ML, Maki T, Hartner W, De Fazio S, Gozzo JJ. Cyclosporine and unresponsiveness to allografts induced by polyclonal antilymphocyte serum and donor-specific bone marrow. Transplant Proc 1988; 20: 36.
12. Wood ML, Gottschalk R, Monaco AP. The effect of cyclosporine on the induction of unresponsiveness in antilymphocyte serum-treated, marrow injected mice. Transplantation 1988; 46: 449.
13. Hale DA, Gottschalk R, Fukuzaki T, Wood ML, Maki T, Monaco AP. Superiority of sirolimus (rapamycin) over cyclosporine in augmenting allograft and xenograft survival in mice treated with antilymphocyte serum and donor-specific bone marrow. Transplantation 1997; 63(3): 359.
14. Caridis DT, Lieogeois A, Barret I, Lytle BW, Monaco AP. Survival of canine renal allografts after antilymphocytic serum and bone-marrow treatment. Br J Surg 1972; 59: 311.
15. Hartner WC, De Fazio SR, Markees TG, Maki T, Monaco AP, Gozzo JJ. Specific tolerance to canine renal allografts following treatment with fractionated bone marrow and antilymphocyte serum. Transplant Proc 1987; 19(1 Pt 1): 476.
16. Thomas FT, Carver FM, Foil MB, et al. Long-term incompatible kidney survival in outbred higher primates without chronic immunosuppression. Ann Surg 1983; 198; 370.
17. Thomas JM, Carver M, Cunningham P, Sash C, Park K, Thomas F. Promotion of incompatible allograft acceptance in rhesus monkeys given posttransplant antithymocyte globulin and donor bone marrow. II. Effects of adjuvant immunosuppressive drugs [published erratum appears in Transplantation 1989 May;47(5):928]. Transplantation 1989; 47: 209.
18. Barber WH, Mankin JA, Laskow DA, et al. Long-term results of a controlled prospective study with transfusion of donor-specific bone marrow in 57 cadaveric renal allograft recipients. Transplantation 1991; 51: 70.
19. Rao AS, Fontes P, Dodson F, et al. Augmentation of natural chimerism with donor bone marrow in orthotopic liver recipients. Transplant Proc 1996; 28(5): 2959.
20. Burke GW, Ciancio G, Garcia-Morales R, et al. Evidence for microchimerism in peripheral blood, bone marrow, and skin following donor bone marrow/kidney-pancreas transplantation at 3 years. Transplant Proc 1998; 30(4): 1555.
21. Groth CG, Backman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group [see comments]. Transplantation 1999; 67(7): 1036.
22. Longoria J, Roberts RF, Marboe CC, Stouch BC, Starnes VA, Barr ML. Sirolimus (rapamycin) potentiates cyclosporine in prevention of acute lung rejection. J Thorac Cardiovasc Surg 1999; 117(4): 714.
23. Watson CJ, Friend PJ, Jamieson NV, et al. Sirolimus: a potent new immunosuppressant for liver transplantation. Transplantation 1999; 67(4): 505.
24. Stratta RJ, Taylor RJ, Weide LG, et al. A prospective randomized trial of OKT3 vs ATGAM induction therapy in pancreas transplant recipients. Transplant Proc 1996; 28: 917.
25. Cho SI, Bradley JW, Carpenter CB, Cosimi AB, Monaco AP. Antithymocyte globulin, pretransplant blood transfusion, and tissue typing in cadaver kidney transplantation. Am J Surg 1983; 145: 464.
26. Illner WD, Theodorakis J, Abendroth D, et al. Quadruple-drug induction therapy in combined renal and pancreatic transplantation: OKT3 versus ATG. Transplant Proc 1990; 22: 1586.
27. Medin JA, Brandt JE, Rozler E, et al. Ex vivo expansion and genetic marking of primitive human and baboon hematopoietic cells. Ann N Y Acad Sci 1999; 872: 233.
28. Albella B, Segovia JC, Guenechea G, Pragnell IB, Bueren JA. Preserved long-term repopulation and differentiation properties of hematopoietic grafts subjected to ex vivo expansion with stem cell factor and interleukin 11. Transplantation 1999; 67(10): 1348.
29. Srour EF, Abonour R, Cornetta K, Traycoff CM. Ex vivo expansion of hematopoietic stem and progenitor cells: are we there yet? J Hematother 1999; 8(2): 93.
30. Wood ML, Monaco AP, Gozzo JJ, Liegeois A. Use of homozygous allogeneic bone marrow for induction of tolerance with antilymphocyte serum: dose and timing. Transplant Proc 1971; 3: 676.
31. Billingham RE, Brent L, Medawar PB. The technique of free skin grafting in mammals. J Exp Biol 1951; 28: 385.
32. Bobbio SA, Wood ML, Monaco AP. Significant augmentation of specific unresponsiveness by rapamycin in ALS-treated, bone marrow injected mice. Transplant Sci 1993; 3: 51.
33. Hale D, Gottschalk R, Maki T, Monaco AP. Use of pharmacologic immunosuppression to augment the specific unresponsiveness (tolerance) to skin allografts induced by donor-specific bone marrow in antilymphocyte serum-treated mice: the unique effect of sirolimus. Transplant Proc 1998; 30(5): 2432.
34. Colson YL, Wren SM, Schuchert MJ, et al. A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers. J Immunol 1995; 155(9): 4179.
35. Markees TG, Phillips NE, Gordon EJ, et al. Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4(+) T cells, interferon-gamma, and CTLA4. J Clin Invest 1998; 101(11): 2446.
36. Kirk AD, Harlan DM, Armstrong NN, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA 1997; 94(16): 8789.
37. Li Y, Zheng XX, Li XC, Zand MS, Strom TB. Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment. Transplantation 1998; 66(10): 1387.
38. Kirk AD, Burkly LC, Batty DS, et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates [sec comments]. Nat Med 1999; 5(6): 686.
39. Norin AJ, Emeson EE. Effects of restoring lethally irradiated mice with anti-Thy 1.2-treated bone marrow: graft-vs-host, host-vs-graft, and mitogen reactivity. J Immunol 1978; 120: 754.
40. Chester CH, Sykes M, Sachs DH. The recovery of resistance to alloengraftment following lethal irradiation and administration of T cell-depleted syngeneic bone marrow. Bone Marrow Transplant 1989; 4: 195.
41. Ildstad ST, Wren SM, Bluestone JA, Barbieri SA, Stephany D, Sachs DH. Effect of selective T cell depletion of host and/or donor bone marrow on lymphopoietic repopulation, tolerance, and graft-vs-host disease in mixed allogeneic chimeras (B10 + B10.D2 - B10). J Immunol 1986; 136: 28.
42. Neipp M, Exner BG, Ildstad ST. A nonlethal conditioning approach to achieve engraftment of xenogeneic rat bone marrow in mice and to induce donor-specific tolerance. Transplantation 1998; 66(8): 969.
43. Li H, Abou el-Ezz AY, Gambrell BE, Ildstad ST. Mixed xenogeneic chimerism and tolerance. III. A nonlethal approach to induce donor-specific transplantation tolerance to simultaneous islet xenografts. Transplantation 1995; 60(1): 59.
44. Zhang QW, Mayumi H, Umesue M, Tomita Y, Nomoto K, Yasui H. Fractionated dosing of cyclophosphamide for establishing long-lasting skin allograft survival, stable mixed chimerism, and intrathymic clonal deletion in mice primed with allogeneic spleen cells. Transplantation 1997; 63(11): 1667.
45. Mayumi H, Umesue M, Nomoto K. Cyclophosphamide-induced immunological tolerance: an overview. Immunobiology 1996; 195(2): 129.
46. Elwood ET, Larsen CP, Maurer DH, et al. Microchimerism and rejection in clinical transplantation [see comments]. Lancet 1997; 349(9062): 1358.
47. Ishida H, Kawai T, Tanabe K, et al. Status of microchimerism in recipients 15 years after living related kidney transplantation. Transplantation 1996; 62(1): 126.
48. Kawai T, Cosimi AB, Colvin RB, et al. Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation 1995; 59: 256.
49. Jacobsen N, Taaning E, Ladefoged J, Kristensen JK, Pedersen FK. Tolerance to an HLA-B,DR disparate kidney allograft after bone-marrow transplantation from same donor [Letter]. Lancet 1994; 343(8900): 800.
50. Sayegh MH, Fine NA, Smith JL, Rennke HG, Milford EL, Tilney NL. Immunologic tolerance to renal allografts after bone marrow transplants from the same donors [see comments]. Ann Intern Med 1991; 114: 954.
51. Helg C, Chapuis B, Bolle JF, et al. Renal transplantation without immunosuppression in a host with tolerance induced by allogeneic bone marrow transplantation. Transplantation 1994; 58: 1420.
52. Wood K, Sachs DH. Chimerism and transplantation tolerance: cause and effect. Immunol Today 1996; 17(12); 584.
53. Sharabi Y, Abraham VS, Sykes M, Sachs DH. Mixed allogeneic chimeras prepared by a non-myeloablative regimen: requirement for chimerism to maintain tolerance. Bone Marrow Transplant 1992; 9: 191.
54. Sykes M, Szot GL, Swenson KA, Pearson DA. Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning. Nat Med 1997; 3(7): 783.
55. Morris RE. Rapamycins: antifungal, antitumor, antiproliferative, and immunosuppressive macrolides. Transplant Rev 1992; 6: 39.
56. Khan A, Tomita Y, Sykes M. Thymic dependence of loss of tolerance in mixed allogeneic bone marrow chimeras after depletion of donor antigen: peripheral mechanisms do not contribute to maintenance of tolerance. Transplantation 1996; 62(3): 380.
57. Hale DA, Gottschalk R, Wood ML, Maki T, Monaco AP. Prolongation of skin allograft survival in mice treated with CTLA-4 Ig in combination with rapamycin or cyclosporine. Transplant Proc 1996; 28(6): 3270.
58. Hale DA, Gottschalk R, Fukuzaki T, Wood ML, Maki T, Monaco AP. Extended skin allo-and xenograft survival in mice treated with rapamycin, antilymphocyte serum, and donor-specific bone marrow transfusion. Transplant Proc 1996; 28(6): 3269.
59. Thomas G. p70s6 k/p85s6 k: mechanism of activation, effects of rapamycin and role in mitogenesis. [Review]. Biochem Soc Trans 1993; 21: 901.
60. Ferrari S, Pearson RB, Siegmann M, Kozma SC, Thomas G. The immunosuppressant rapamycin induces inactivation of p70s6 k through dephosphorylation of a novel set of sites. J Biol Chem 1993; 268: 16091.
61. Flanagan WM, Crabtree GR. Rapamycin inhibits p34cdc2 expression and arrests T lymphocyte proliferation at the G1/S transition. Ann N Y Acad Sci 1993; 696: 31.
62. Cardenas ME, Zhu D, Heitman J. Molecular mechanisms of immunosuppression by cyclosporine, FK506, and rapamycin. Curr Opin Nephrol Hypertens 1995; 4(6): 472.
63. Staruch MJ, Sigal NH, Dumont FJ. Differential effects of the immunosuppressive macrolides FK-506 and rapamycin on activation-induced T-cell apoptosis. Int J Immunopharmacol 1991; 13: 677.
64. Li XC, Zheng XX, Strom TB. T-cell growth factors in allograft rejection and tolerance. Transplant Proc 1999; 31(1-2): 342.
65. Colson YL, Li H, Boggs SS, Patrene KD, Johnson PC, Ildstad ST. Durable mixed allogeneic chimerism and tolerance by a non-lethal radiation-based cytoreductive approach. J Immunol 1996; 157(7): 2820.
66. Tomita Y, Sachs DH, Khan A, Sykes M. Additional monoclonal antibody (mAB) injections can replace thymic irradiation to allow induction of mixed chimerism and tolerance in mice receiving bone marrow transplantation after conditioning with anti-T cell mABs and 3-Gy whole body irradiation. Transplantation 1996; 61(3): 469.
67. Emerson SG. Ex vivo expansion of hematopoietic precursors, progenitors, and stem cells: the next generation of cellular therapeutics. Blood 1996; 87(8): 3082.
68. Tabilio A, Falzetti F, Giannoni C, et al. Stem cell mobilization in normal donors. J Hematother 1997; 6(3): 227.
69. Aversa F, Tabilio A, Terenzi A, et al. Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 1994; 84(11): 3948.